Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture

1. A glucopyranosyl-substituted benzonitrile derivative selected from the list according to formula II, III, or i.2,

wherein

R 3 is cyclopentyloxy, cyclobutyloxy, cyclohexyloxy, tetrahydropyran-4-yloxy, 1-acetyl-piperidin-4-yloxy or C 1-3 -alkyloxy, and

R′ denotes H, C 1-4 -alkyl, (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, arylcarbonyl or aryl-(C 1-3 -alkyl)-carbonyl, wherein the alkyl or aryl groups may be mono- or polysubstituted by halogen;

R 8a , R 8b , R 8c , R 8d independently of one another denote hydrogen or an allyl group, a benzyl group, a (C 1-4 -alkyl)carbonyl, (C 1-4 -alkyl)oxycarbonyl, arylcarbonyl, aryl-(C 1-3 -alkyl)-carbonyl and aryl-(C 1-3 -alkyl)-oxycarbonyl or a R a R b R c Si group or a ketal or acetal group, particularly an alkylidene or arylalkylidene ketal or acetal group, while in each case two adjacent groups R 8a , R 8b , R 8c , R 8d may form a cyclic ketal or acetal group or a 1,2-di(C 1-3 -alkoxy)-1,2-di(C 1-3 -alkyl)-ethylene bridge, while the above-mentioned ethylene bridge forms, together with two oxygen atoms and the two associated carbon atoms of the pyranose ring, a substituted dioxane ring, particularly a 2,3-dimethyl-2,3-di(C 1-3 -alkoxy)- 1,4-dioxane ring, and while alkyl, allyl, aryl and/or benzyl groups may be mono- or polysubstituted by halogen or C 1-3 -alkoxy, and while benzyl groups may also be substituted by a di-(C 1-3 -alkyl)amino group; and

R a , R b , R c independently of one another denote C 1-4 -alkyl, aryl or aryl-C 1-3 -alkyl, wherein the aryl or alkyl groups may be mono- or polysubstituted by halogen;

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups; and

Alk denotes C 1-4 -alkyl.

2. A glucopyranosyl-substituted benzonitrile derivative selected from the group consisting of:

(1) 2-(4-Cyclopentyloxy-benzyl)-4-(β-D-glucopyranos- 1-yl)-benzonitrile,

(2) 2-(4-Cyclobutyloxy-benzyl)-4-(β-D-glucopyranos- 1-yl)-benzonitrile,

(3) 2-(4-Cyclohexyloxy-benzyl)-4-(β-D-glucopyranos- 1-yl)-benzonitrile,

(4) 2-[4-(Tetrahydropyran-4-yloxy)-benzyl]-4-(β-D-glucopyranos-1-yl)-benzonitrile,

(5) 2-[4-(1-Acetyl-piperidin-4-yloxy)-benzyl]-4-(β-D-glucopyranos-1-yl)-benzonitrile,

(6) 2-(4-Methoxy-benzyl)-4-(β-D-glucopyranos- 1-yl)-benzonitrile,

(7) 2-(4-Ethoxy-benzyl)-4-(β-D-glucopyranos- 1-yl)-benzonitrile,

(8) 4-(β-D-glucopyranos-1-yl)-2-(4-isopropoxy-benzyl)-benzonitrile,

or a derivative thereof wherein one or more hydroxyl groups of the β-D-glucopyranosyl group are acylated with groups selected from (C 1-18 -alkyl)carbonyl, (C 1-18 -alkyl)oxycarbonyl, phenylcarbonyl and phenyl-(C 1-3 -alkyl)-carbonyl.

3. Glucopyranosyl-substituted benzonitrile derivative according to claim 2 , wherein the hydrogen atom of the hydroxyl group O-6 of the β-D-glucopyranosyl-group is replaced by a group selected from among (C 1-8 -alkyl)carbonyl, (C 1-8 -alkyl)oxycarbonyl and phenylcarbonyl.

4. Pharmaceutical composition, comprising a compound according to claim 2 optionally together with one or more inert carriers and/or diluents.

5. A method of treating diseases or conditions which can be influenced by inhibiting the sodium-dependent glucose cotransporter SGLT said method comprised of the steps of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 , wherein said disease or condition is selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia.

6. A method of treating metabolic disorders, said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 , wherein said metabolic disorders is selected from the group consisting of type 1 and type 2 diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia, glucose metabolic disorder, insulin resistance, metabolic syndrome, dyslipidaemias of different origins, atherosclerosis and related diseases, obesity, high blood pressure, chronic heart failure, edema and hyperuricaemia.

7. A method of inhibiting the sodium-dependent glucose cotransporter SGLT2, said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 .

8. A method of treating the degeneration of pancreatic beta cells and/or for improving the functionality of beta cells, said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 .

9. A method of slowing, delaying or treating diseases or conditions attributed to abnormal accumulation of liver fat, said method comprised of the step of administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 2 .

10. A glucopyranosyl-substituted benzonitrile derivative according to claim 1 , wherein R 3 is methoxy, ethoxy or isopropoxy.

11. A glucopyranosyl-substituted benzonitrile derivative according to claim 1 , wherein said aryl groups are phenyl groups.